Chemocentryx, Inc. (CCXI) Files Form 4 Insider Buying : Geoffrey M. Parker Buys 40,000 Shares

Chemocentryx, Inc. (CCXI): Geoffrey M. Parker , director of Chemocentryx, Inc. purchased 40,000 shares on May 13, 2016. The Insider buying transaction was reported by the company on May 13, 2016 to the Securities and Exchange Commission. The shares were purchased at $4.03 per share for a total value of $161,388.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jan 22, 2016, Susan M Kanaya (SVP, Finance, CFO and Sec.) sold 25,764 shares at $4.04 per share price.On Jan 11, 2016, Geoffrey M. Parker (director) purchased 20,000 shares at $4.63 per share price.Also, On May 26, 2015, Ira Klein (director) sold 10,811 shares at $7.45 per share price.On May 26, 2015, James L Tyree (director) sold 12,703 shares at $7.45 per share price.

ChemoCentryx Inc: On Tuesday, May 10, 2016 heightened volatility was witnessed in ChemoCentryx Inc which led to swings in the share price. The shares opened for trading at $3.78 and hit $3.93 on the upside , eventually ending the session at $2.99, with a gain of 42.38% or 0.89 points. The heightened volatility saw the trading volume jump to 1,51,42,423 shares. The 52-week high of the share price is $9.46 and the company has a market cap of $132 M . The 52-week low of the share price is at $1.9214.

ChemoCentryx Inc Money Flow Index Chart

ChemoCentryx Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering developing and commercializing orally-administered therapeutics to treat autoimmune diseases inflammatory disorders and cancer. It targets the chemoattractant system which is a network of molecules including chemokine ligands and their associated receptors as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. The Company’s product portfolio includes CCX140 CCX872 CCX168 Vercirnon (Traficet-EN or CCX282) and CCX507.

Leave a Reply

ChemoCentryx Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on ChemoCentryx Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.